NEW YORK (GenomeWeb News) – DeltaDot will partner with the Qatar Science and Technology Park to open a proteomics research and testing services lab in Doha, the London-based company said on Monday.

Under the plan, QSTP will contribute $15 million to the partnership, while DeltaDot will provide staff, expertise, and it will grant QSTP an exclusive regional license to its technology.

Projects already in the works include biomarker studies for breast cancer and colorectal cancer and the metallic content of proteins, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.